Q-omics provides the consensus-scored ZNF395 profile across patient tissues and cancer cell-line models. ZNF395 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in READ. Among the 18 cancer types available for tumor–normal comparison, ZNF395 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, ZNF395 RNA expression shows 19,829 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight READ, KIRC, and ACC as cancer lineages where ZNF395 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF395 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF395 survival associations across molecular data types. ZNF395 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF395 RNA expression–survival associations across cancer types. High ZNF395 expression shows unfavorable associations in KICH and LIHC, but favorable associations in READ, KIRC, UVM and THYM. The READ Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify READ as the clearest survival context for ZNF395 RNA expression.
This table summarizes ZNF395 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ZNF395. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF395 shows lower tumor expression in LUAD, BRCA, KICH and THCA and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher ZNF395 RNA expression in tumor versus normal tissue (log2 FC = +2.817, t-test p < 0.001).
This table shows molecular features associated with ZNF395 in patient tissues and cancer cell lines. In patient samples, ZNF395 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF395 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
